会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 63. 发明授权
    • Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy
    • 使用MiR-26家族作为肝细胞癌的预测指标和对治疗的反应
    • US09125923B2
    • 2015-09-08
    • US12997419
    • 2009-06-11
    • Xin W. WangJunfang JiCarlo M. CroceHui-chuan SunZhao-you Tang
    • Xin W. WangJunfang JiCarlo M. CroceHui-chuan SunZhao-you Tang
    • C40B30/04A61K31/70C12Q1/68
    • A61K31/70A61K38/212C12Q1/6809C12Q1/6886C12Q2600/106C12Q2600/112C12Q2600/136C12Q2600/178C12Q2525/207
    • It is disclosed herein that expression of microRNA-26 is decreased in hepatocellular (HCC) tumor tissue relative to non-cancerous tissue, and that a low level of microRNA-26 is associated with a poor clinical outcome. It is also disclosed herein that a low expression level of microRNA-26 is correlated with a favorable response to interferon (IFN)-α therapy in HCC patients. Thus, provided herein is a method of predicting the clinical outcome of a patient diagnosed with HCC comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. Also provided is a method of selecting a patient diagnosed with HCC as a candidate for IFN-α therapy, comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. A method of identifying therapeutic agents for the treatment of HCC, comprising screening candidate agents in vitro to select an agent that increases expression of microRNA-26 in HCC cells are also provided. Further provided are methods of treating a patient diagnosed with HCC and expressing a low level of miR-26, wherein treatment comprises IFN-α therapy.
    • 本文公开了相对于非癌组织,肝细胞(HCC)肿瘤组织中microRNA-26的表达降低,并且低水平的microRNA-26与不良临床结果相关。 本文还公开了低表达水平的微小RNA-26与HCC患者中对干扰素(IFN)-α治疗的有利反应相关。 因此,本文提供了一种预测诊断为HCC的患者的临床结果的方法,包括检测从患者获得的样品中的microRNA-26表达水平。 还提供了选择被诊断为HCC的患者作为IFN-α治疗的候选者的方法,包括检测从患者获得的样品中的microRNA-26表达水平。 还提供了鉴定用于治疗HCC的治疗剂的方法,其包括在体外筛选候选试剂以选择增加HCC细胞中微小RNA-26表达的试剂。 还提供了治疗诊断为HCC并表达低水平的miR-26的患者的方法,其中治疗包括IFN-α治疗。